


Small-Molecule Hepatocyte Growth Factor/MET Positive Modulators Effectively Reduce Pain-Related Behaviors in a Rat Model of Diabetic Neuropathy

Andrée-Anne Berthiaume, Kayla Kleist, Robert Taylor, Jewel Johnston, Kevin J. Church
Athira Pharma, Inc., Bothell, WA, USA

SUPPLEMENTAL INFORMATION


Supplemental Figure S1. Body weight is consistent across all DNP experimental groups



Rats in all diabetic neuropathic pain (DNP) groups had similarly decreased lower body weight throughout the study duration, regardless of treatment group (two-way analysis of variance [ANOVA] with Dunnett test vs DNP control).

**** $P < 0.0001$.

Supplemental Figure S2. Serum glucose levels are elevated in all DNP groups after streptozotocin (STZ) administration



Rats across all DNP groups had similarly increased serum glucose levels four days after STZ administration, indicating successful induction of the diabetic phenotype (one-way ANOVA with Dunnett test vs DNP control).

**** $P < 0.0001$.

Abbreviations ANOVA, analysis of variance; **DNP**, diabetic neuropathic pain; **STZ**, streptozotocin.

Acknowledgments

This study was sponsored by Athira Pharma, Inc. Medical writing support was provided by Katie Henderson, PhD, of ApotheCom, and funded by Athira Pharma, Inc.

Disclosures

Andrée-Anne Berthiaume, Kayla Kleist, Robert Taylor, Jewel Johnston, and Kevin J. Church are employees and stockholders of Athira Pharma, Inc.

© Athira Pharma, Inc. All Rights Reserved.

Presented at Neuroscience 2022;
November 12-16, 2022; San Diego, California